BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 23074235)

  • 1. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
    Luconi M; Mangoni M; Gelmini S; Poli G; Nesi G; Francalanci M; Pratesi N; Cantini G; Lombardi A; Pepi M; Ercolino T; Serio M; Orlando C; Mannelli M
    Endocr Relat Cancer; 2010 Mar; 17(1):169-77. PubMed ID: 19955217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells.
    Bryant W; Snowhite AE; Rice LW; Shupnik MA
    Endocrinology; 2005 Feb; 146(2):751-9. PubMed ID: 15528307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
    Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation.
    Montanaro D; Maggiolini M; Recchia AG; Sirianni R; Aquila S; Barzon L; Fallo F; Andò S; Pezzi V
    J Mol Endocrinol; 2005 Oct; 35(2):245-56. PubMed ID: 16216906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
    Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
    J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
    Eertmans F; Dhooge W; De Wever O; Bracke M; Comhaire F; Kaufman JM
    J Cell Physiol; 2007 Sep; 212(3):583-90. PubMed ID: 17458895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
    Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
    Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth.
    De Luca A; Avena P; Sirianni R; Chimento A; Fallo F; Pilon C; Casaburi I; Pezzi V
    Cells; 2017 Nov; 6(4):. PubMed ID: 29112114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation.
    Sirianni R; Chimento A; Malivindi R; Mazzitelli I; Andò S; Pezzi V
    Cancer Res; 2007 Sep; 67(17):8368-77. PubMed ID: 17804753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
    Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
    J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
    Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
    Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.